Companies › Seaport Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SPT-300 (GlyphAllo) Allopregnanolone prodrug; positive allosteric modulator of GABA-A receptors | GABRA1 | Phase 2 | Major Depressive Disorder (MDD) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07065240 | SPT-300 (GlyphAllo) | Phase 2 | Major Depressive Disorder (MDD) | Psychiatry | Mar 2027 |
Cash and short-term investments of $290m on 2026-09-30; operating cash outflow about $93m a year; runway about 38 months at that burn, to Nov 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group Neurodawn Pharmaceutical SK Life Science Sedana Medical Acacia Pharma Umecrine Cognition
Anavex Life Sciences Definium Therapeutics US Draig Therapeutics Kadence Bio HB BioTech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.